In randomised clinical trials (RCTs), endovascular thrombectomy (ET) was combined with intravenous thrombolysis (IVT) in the vast majority of patients. We aimed to analyse how German stroke centres manage IVT in patients receiving ET in daily routine.
Introduction
Intravenous thrombolysis (IVT) is the standard of care in hyperacute ischemic stroke and up to 40% of acute ischemic stroke patients receive IVT in Germany. 1, 2 In 2015, five randomised controlled trials (RCTs) demonstrated superiority for endovascular thrombectomy (ET) plus IVT in comparison to IVT alone in patients with large vessel occlusion of the anterior circulation. [3] [4] [5] [6] [7] In two of the five trials, only patients treated with IVT were considered for enrollment, and in the other three trials the vast majority of patients received IVT prior to ET (68-87%). [3] [4] [5] [6] [7] Altogether, 85% of patients received IVT in addition to ET. 8 Current European and German recommendations as well as the guidelines from the American Heart Association recommend that ET should not prevent IVT and IVT should not delay ET in acute stroke if both therapies are indicated. 9- 11 We aimed to determine, how the management of IVT together with ET is handled in clinical practice in Germany.
Patients and methods
We performed a literature search via PubMed between 2013 and 2016 and did not find any data regarding the question how the management of IVT together with ET is handled in clinical practice. Therefore we invited neurologists and neurointerventionalists from all German University hospitals, all participants of the German Stroke Registry -Endovascular Treatment (GSR), and a selected list of German Hospitals known to perform ET to participate in an online survey. Overall, we sent out 246 invitations to 115 different centres. Centres included all German University-Hospitals (n ¼ 37) and other centres known to perform ET (n ¼ 78). The overall response rate was 110/246 (45%). Invitations were sent to each identifiable stroke neurologist of the local centres (n ¼ 196) and to all available neuroradiologists (n ¼ 46). Four invitations were sent to other specialists known to perform ET. The survey was performed using an internet based questionnaire provided by a commercially available survey system (https://www.surveymonkey.de). 
Results
Overall, we received 110 replies, 76% (84/110) from neurologists and 20% (22/110) from neurointerventionalists, 68 of 110 (62%) answers were received anonymised. About 65% (65/100) of participants in our cohort stated to perform more than 50 ET per year, 18% (18/100) stated to perform between 20 and 50 and only 17% (17/100) mentioned to perform less than 20 annual procedures. Please see Table 1 for further detailed baseline data.
The majority of participants (75/99, 76%) reported to continue IVT after ET was started. Nine participants (9/99, 9%) reported to stop IVT as a standard of care before ET and another 15/99 (15%) to stop IVT as an individual case decision (see Figure 1 ). If stopping IVT, the time of stopping is before groin puncture in 17% (4/24), during ET (immediately prior thrombus retrieval) in 46% (11/24) or at any other time in 37% (9/24). Nine participants (9/24, 37%) do not re-continue with IVT after ET. Fifteen participants (15/24, 63%) proceed with IVT after ET on the basis of an individual case decision e.g. depending on thrombolysis in cerebral infarction (TICI) grade or dislocation of thrombus to distal arteries. Yes Recombinant tissue plasminogen Activator (rtPA) is given intra-arterially in individual cases in 39% (37/99) and as a standard of care in 3% (3/99) (see Figure 2 ). Intra-arterial Heparin is given additionally as a standard of care in 25% (24/96) and in 11% (11/96) in individual cases. IVT is omitted without contraindications before ET in total in 19% (18/96) thereof in 5% (5/96) as a standard of care and in 14% (13/96) in individual cases. The importance of IVT in drip-and-ship patients was considered as very important (53/95, 56%), important (33/95, 35%), not important (8/95, 9%), needless (1/95, 1%) and harmful (0/95, 0%) and in patients treated directly in a comprehensive stroke centre (''mothership'') as very important (42/96, 44%), important (43/96, 45%), not important (7/96, 7%), needless (4/96, 4%) and harmful (0/96, 0%).
Discussion
This national survey showed a wide heterogeneity with respect to management of IVT in the setting of ET. Almost one quarter of participants reported to stop IVT before ET at least in individual cases, mostly before start of the thrombectomy manoeuvre. Moreover, nearly 20% of participants stated to withhold IVT before planned ET even in the absence of contraindications against IVT. This is noteworthy, as neither current guideline recommendations, nor the results from the large clinical trials of thrombectomy support such an approach. Furthermore some centres (re-) start IVT after ET in certain constellations (e.g. depending on TICI grade) while others generally do not proceed with IVT after ET or generally stop IVT after ET irrespective of success of recanalisation.
Besides, this survey reveals a high variability with regard to dosing and type of antithrombotic medication. This is highlighted by the fact that about one-third give variable parts of the rtPA dose intraarterially and about one-third administer additional Heparin in different dose regimes. The majority of patients within RCTs received the full dose of IVT for that reason alone that time between IVT and groin puncture exceeded 60 min (median time from initiation of IVT to groin puncture 74-175 min). [3] [4] [5] [6] [7] Nevertheless, without the procedure of randomisation and an increased speed of clinical routine the time interval from IVT to groin puncture may shorten to less than 60 min in a substantial number of patients. In this situation evidence for most of the above mentioned variations in ET is obviously hard to find.
In other situations, evidence may even stand in contradiction to personal experiences of the treating physicians. Besides, it should be noted that an IVT stop immediately prior to ET or groin puncture appears of limited effect due to pathophysiological considerations. Although there is a fast clearance of rtPA from the bloodstream with a half-life of 4-5 min it must be noted, that the rtPA half-life for deeper tissue compartments is 40 min and the decrease in fibrinogen levels reaches its maximum after 6 h. 12 This consideration is in line with the fact that intracerebral bleeding complications do not occur within minutes but mostly within the first 24-36 h after IVT. 1, 13 However, the benefit of IVT in combination with ET is not only a matter of debate in daily German stroke care but also in recent literature: retrospective analyses suggested a limited effect of IVT when combined with ET although up to now there are no clinical trials showing efficacy of ET without IVT. [14] [15] [16] Although this study is unique and the vast majority of participants in this survey can be considered as representatives from high volume centres, our study has several limitations. The results cannot be considered as representative for German acute stroke care in general. Nevertheless, this would not affect our main conclusion that a wide heterogeneity in IVT management is present. We further had no strict inclusion or exclusion criterion for centres to participate; however, the vast majority of participants stated a large experience with IVT and ET. Due to the possibility of anonymous participation, we could not control for incorrect or double answers. However, the results remained stable, when looking only at participants with open identity (data not shown). Some questions regarding stop and restart of thrombolysis might have been hypothetical in centres where IVT is generally fully administered due to long procedural time intervals.
Conclusion
For the first time, this national survey addresses important questions of ET management in daily stroke care. The large heterogeneity on how to proceed with IVT in the context of ET demonstrates urgent need for implementation of rational medical standards from recent trials. Where evidence is not available, further clinical trials are warranted. Until then, we propose to comply with the current guidelines that are based on recent trials and pathophysiological considerations and recommend both IVT and ET not prevent each other.
